FZ-AD005

FZ-AD005 is a DLL3 target ADC compound containing a novel anti-DLL3 antibody, FZ-A038, and a valine–alanine (Val–Ala) dipeptide linker. FZ-AD005 can used in the research of small cell lung cancer[1].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/fz-ad005.html

Purity

97.27

Smiles

[FZ-AD005]

References & Citations

[1]Qingsong Guo, et al. FZ-AD005, a Novel DLL3-Targeted Antibody–Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models. Mol Cancer Ther. 2024 Jun 28;23 (10) :1367–1377.